You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

The Gut-Kidney Axis in IgA Nephropathy: Novel Insights and Emerging Treatment Options

  • Authors: Jonathan Barratt, PhD, FRCP​; Richard Lafayette, MD, FACP​; Dana Rizk, MD
  • CME Released: 12/16/2021
  • Valid for credit through: 12/16/2022
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for nephrologists.

The goal of this activity is to increase knowledge about the role of the gut-kidney axis in immunoglobulin A nephropathy (IgAN), how this influences treatment targets, and how novel treatments are addressing this.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current challenges and limitations associated with the diagnosis and management of IgAN 
    • Role of the gut-kidney axis in IgAN 
    • Safety and efficacy of novel therapies for the management of IgAN 


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Jonathan Barratt, PhD, FRCP

    Professor of Renal Medicine
    Department of Cardiovascular Sciences
    University of Leicester
    Nephrologist
    John Walls Renal Unit
    University Hospitals of Leicester NHS Trust
    Leicester, United Kingdom

    Disclosures

    Disclosure: Jonathan Barratt, PhD, FRCP, has the following relevant financial relationships:
    Advisor or consultant for: Alynylam; argenx; Astellas; AstraZeneca; BioCryst; Calliditas; Chinook; Dimerix; Galapagos; Novartis; Omeros; Takeda; Travere Therapeutics; Vera Therapeutics; Visterra; UCB
    Grants for clinical research from: argenx; Calliditas; Chinook; Galapagos; Novartis; Omeros; Travere Therapeutics; Vera Therapeutics; Visterra; UCB
    Ownership of an ineligible company: consulting services Jonathan Barratt Consulting Ltd

  • Richard Lafayette, MD, FACP

    Nephrologist
    Professor of Medicine
    Division of Nephrology
    Department of Medicine
    Stanford University
    Stanford, California, United States

    Disclosures

    Disclosure: Richard Lafayette, MD, FACP, has the following relevant financial relationships:
    Advisor or consultant for: Alexion; Aurinia; Calliditas; Cara; Novartis; Omeros; Roche; Travere Therapeutics; Vera Therapeutics
    Grants for clinical research from: Alexion; Aurinia; Calliditas; Novartis; Omeros; Pfizer; Travere Therapeutics; Vera Therapeutics

  • Dana Rizk, MD

    Professor of Medicine
    Nephrology Division
    Anupam Agarwal MD Endowed Scholar in Nephrology
    Director of Clinical Trials Research
    Nephrology Division
    Medical Director of Clinical Trials Administrative Office
    Birmingham, Alabama, United States

    Disclosures

    Disclosure: Dana Rizk MD, has the following relevant financial relationships:
    Advisor or consultant for: Angion; Calliditas; George Clinical; Novartis; Visterra/Otsuka
    Grants for clinical research from: Calliditas; Morphosys; Reata; Retrophin; Vertex; Visterra/Otsuka
    Stocks, stock options, or bonds from: Co-founder and co-owner of Reliant Glycosciences LLC

Editor

  • Rita Moreira Da Silva, PharmD, MA, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Rita Moreira Da Silva, PharmD, MA, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

The Gut-Kidney Axis in IgA Nephropathy: Novel Insights and Emerging Treatment Options

Authors: Jonathan Barratt, PhD, FRCP​; Richard Lafayette, MD, FACP​; Dana Rizk, MDFaculty and Disclosures

CME Released: 12/16/2021

Valid for credit through: 12/16/2022

processing....

In December 2021, the US Food and Drug Administration approved budesonide delayed-release capsules as a treatment indicated to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5g/g. 

Assessment Survey

Before you begin, please take this brief survey.